CKD Understanding risk factors for progressive chronic kidney disease in Malawi to inform interventions for earlier detection and prevention (Impso Study)
Malawi
Reference ID
DDI-MWI-MEIRU-CKDK-2024-v1
Producer(s)
Charlotte Snead
Collections
Created on
May 21, 2026
Last modified
May 21, 2026
Page views
21788
Downloads
202
Baseline/followup (base_basefoll)
Data file: ckdk_fieldlog_fu2
Overview
Valid:
12
Invalid:
6
Type:
Discrete
Decimal:
0
Start:
270
End:
272
Width:
3
Range:
-
Format:
Numeric
Questions and instructions
Literal question
base_basefoll
Categories
| Value | Category | Cases | |
|---|---|---|---|
| 1 | Visit 1 | 0 |
0%
|
| 2 | TSD/GSC-2 month follow up | 0 |
0%
|
| 3 | ART-2 month follow up | 0 |
0%
|
| 4 | Visit 4 | 0 |
0%
|
| 6 | 6 month follow up | 0 |
0%
|
| 8 | 8 week follow up | 0 |
0%
|
| 9 | 9 month follow up | 0 |
0%
|
| 10 | 10 week follow up | 0 |
0%
|
| 12 | 12 month follow up | 0 |
0%
|
| 14 | 14 week follow up | 0 |
0%
|
| 15 | 15 month follow up | 0 |
0%
|
| 16 | 16 week follow up | 0 |
0%
|
| 18 | 18 month follow up | 0 |
0%
|
| 21 | 21 month follow up | 0 |
0%
|
| 24 | 24 month follow up | 0 |
0%
|
| 26 | 26 week follow up | 0 |
0%
|
| 27 | 27 month follow up | 0 |
0%
|
| 30 | 30 month follow up | 0 |
0%
|
| 33 | 33 month follow up | 0 |
0%
|
| 36 | 36 month follow up | 0 |
0%
|
| 39 | 39 month follow up | 0 |
0%
|
| 42 | 42 month follow up | 0 |
0%
|
| 52 | ????????????? | 0 |
0%
|
| 100 | Week O6 - Control | 0 |
0%
|
| 101 | Week 26 - Control | 0 |
0%
|
| 102 | Acute episode | 0 |
0%
|
| 103 | AHS-Stage 1 | 0 |
0%
|
| 104 | ARV-Stage 1 | 0 |
0%
|
| 105 | Baby 1 | 0 |
0%
|
| 106 | Baseline fasting | 0 |
0%
|
| 107 | Baseline | 12 |
100%
|
| 108 | Baseline random | 0 |
0%
|
| 109 | Child's sample | 0 |
0%
|
| 110 | Cord blood | 0 |
0%
|
| 111 | excluded - LIS hiv positives | 0 |
0%
|
| 113 | Follow up | 0 |
0%
|
| 114 | Glucose tolerance | 0 |
0%
|
| 115 | iohex 1 | 0 |
0%
|
| 116 | iohex 2 | 0 |
0%
|
| 117 | iohex 3 | 0 |
0%
|
| 118 | iohex 4 | 0 |
0%
|
| 119 | IIB follow up 1 | 0 |
0%
|
| 120 | Initial screening | 0 |
0%
|
| 121 | LIS clinical review | 0 |
0%
|
| 122 | Mother's sample | 0 |
0%
|
| 123 | Old - toxoplasmosis test required | 0 |
0%
|
| 124 | Old | 0 |
0%
|
| 125 | Pre baseline | 0 |
0%
|
| 126 | Gates Controls suspected to be progressor | 0 |
0%
|
| 127 | PVC follow up week 1 | 0 |
0%
|
| 128 | PVC 12 week follow up | 0 |
0%
|
| 129 | PVC 18 week follow up | 0 |
0%
|
| 130 | PVC 4 week follow up | 0 |
0%
|
| 131 | PVC 6 week follow up | 0 |
0%
|
| 132 | Randomisation screening | 0 |
0%
|
| 133 | Stimulated with BCG | 0 |
0%
|
| 134 | Unstimulated | 0 |
0%
|
| 135 | Young - sickle cell test and toxoplasmosis test required | 0 |
0%
|
| 136 | Young - sickle cell test | 0 |
0%
|
| 137 | NTN pilot1 | 0 |
0%
|
| 138 | Delivery | 0 |
0%
|
| 139 | Week one | 0 |
0%
|
| 140 | Week six | 0 |
0%
|
| 141 | Week sixteen | 0 |
0%
|
| 142 | Third trimister | 0 |
0%
|
| 998 | Unknown | 0 |
0%
|
| 999 | Missing | 0 | |
| Sysmiss | 6 |
Warning: these figures indicate the number of cases found in the data file. They cannot be interpreted as summary statistics of the population of interest.